Zacks Research Has Optimistic Outlook of CRSP Q2 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Equities research analysts at Zacks Research upped their Q2 2025 EPS estimates for shares of CRISPR Therapeutics in a note issued to investors on Tuesday, March 4th. Zacks Research analyst R. Department now forecasts that the company will earn ($1.61) per share for the quarter, up from their previous estimate of ($1.65). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. Zacks Research also issued estimates for CRISPR Therapeutics’ Q3 2025 earnings at ($1.42) EPS, Q4 2025 earnings at ($1.28) EPS, FY2025 earnings at ($5.90) EPS, Q1 2026 earnings at ($1.46) EPS, Q2 2026 earnings at ($1.44) EPS, Q3 2026 earnings at ($1.18) EPS, Q4 2026 earnings at ($1.09) EPS and FY2026 earnings at ($5.16) EPS.

Several other research analysts have also issued reports on CRSP. HC Wainwright reiterated a “buy” rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research note on Thursday, February 13th. The Goldman Sachs Group reduced their price objective on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. Truist Financial raised their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, February 12th. Finally, Chardan Capital reduced their price objective on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $74.40.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock opened at $43.84 on Thursday. The company has a 50-day moving average of $42.57 and a 200 day moving average of $45.86. The firm has a market cap of $3.76 billion, a price-to-earnings ratio of -10.03 and a beta of 1.67. CRISPR Therapeutics has a 1 year low of $36.52 and a 1 year high of $83.50.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%.

Insider Transactions at CRISPR Therapeutics

In other news, Director John Greene bought 7,000 shares of CRISPR Therapeutics stock in a transaction dated Wednesday, February 26th. The shares were acquired at an average price of $44.85 per share, with a total value of $313,950.00. Following the completion of the purchase, the director now owns 7,000 shares in the company, valued at $313,950. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Samarth Kulkarni sold 18,360 shares of the company’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the transaction, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. The trade was a 9.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CRSP. ARK Investment Management LLC grew its holdings in CRISPR Therapeutics by 19.7% during the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock worth $353,180,000 after acquiring an additional 1,474,439 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in CRISPR Therapeutics by 39.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company’s stock worth $150,029,000 after acquiring an additional 1,074,238 shares in the last quarter. Capital International Investors grew its holdings in CRISPR Therapeutics by 10.3% during the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company’s stock worth $344,145,000 after acquiring an additional 816,789 shares in the last quarter. Baker BROS. Advisors LP lifted its position in shares of CRISPR Therapeutics by 743.1% during the third quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock valued at $39,608,000 after buying an additional 743,075 shares during the last quarter. Finally, State Street Corp lifted its position in shares of CRISPR Therapeutics by 25.0% during the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after buying an additional 599,304 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.